Wells Fargo & Company Pharma Cyte Biotech, Inc. Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PMCB
# of Institutions
33Shares Held
1.07MCall Options Held
5.4KPut Options Held
400-
K2 Principal Fund, L.P. Toronto, A6328KShares$648,4550.27% of portfolio
-
Geode Capital Management, LLC Boston, MA200KShares$396,5560.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA175KShares$345,7110.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$182,3327.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$163,7990.18% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $41.1M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...